1.
|
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181203, DARENCA STUDY 2, NCT01339962
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 90
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001C2240, 2006-002070-21, NCT00410124
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001C2325, NCT00412061
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001C2324, EudraCT 2006-006819-75, NCT00510068
|
|
5.
|
Phase: Phase III
Type: Genetics, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: GBG 44, EudraCT No.: 2006-005834-19, NCT00567554
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: Any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001M2301, NCT00789828
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001M2302, NCT00790400
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001Y2301, 2008-008698-69, NCT00863655
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001R2301, EUDRACT No. - 2008-006544-20, NCT00879333
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001W2301, 2008-008697-31, NCT01007942
|
|
11.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001O2301, 2009-010196-25, NCT01035229
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: 2003-0948, NCT00081874
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: CDR0000370826, MSKCC-04010, NCT00085566
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: RPCI-PH-24204, NOVARTIS-CRAD001C2207, NCT00093639
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000393199, MSKCC-04033, NCT00096486
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0409004-01, NOVARTIS-CAEE788A2106, NCT00107237
|
|
17.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000454988, DUMC-6626-04-12R0, NCT00303732
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2005-0471, NCT00317720
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI GU 44, CRAD001C2480, NCT00392821
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 1342-2004, NCT00406276
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 3 and over
Sponsor: Other
Protocol IDs: CCHMC IRB# 06-07-50, NCT00411619
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Other
Protocol IDs: RCC-06-102, 1006-0152, NCT00448149
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 65
Sponsor: Other
Protocol IDs: CCHMC IRB #2008-0812(04-07-22), NCT00457964
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 05-184, NCT00459186
|
|
25.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N057K, N057K, NCT00553150
|
Mobile | Español
